The microRNA Transcriptome of Human Cytomegalovirus (HCMV)

The microRNA Transcriptome of Human Cytomegalovirus (HCMV)

The purpose of the present study was to characterize the microRNA transcriptome (miRNAome) of the human cytomegalovirus (HCMV or HHV5). We used deep sequencing and real time PCR (qPCR) together with bioinformatics to analyze the pattern of small RNA expression in cells infected with low-passage isolates of HCMV as well as in plasma and amniotic fluid. We report here on the discovery of four new...

Apoptotic Control in HCMV Retinitis Cytomegalovirus (HCMV) Mediates the The Immediate Early 2 Protein of Human

Spread of human cytomegalovirus (HCMV) after infection of human hematopoietic progenitor cells: model of HCMV latency.

Clinical experience and laboratory data suggest that human cytomegalovirus (HCMV) is present in peripheral blood of seropositive individuals in a latent or persistent state and can be transmitted via blood products and be reactivated in seropositive immunocompromised patients. The pathophysiology of HCMV latency and the nature of HCMV interaction with hematopoietic cells remains unknown. In thi...

PCR optimization: Improving of Human Cytomegalovirus (HCMV) PCR to Achieve a Highly Sensitive Detection Method

Polymerase chain reaction (PCR) is a rapid and simple technique with high sensitivity and specificity. Inthe recent years, PCR has been used for rapid detection of viral nucleic acids, such as Humancytomegalovirus (HCMV), whereas, PCR optimization is an important task to be done, especially beforeit’s diagnostic application. Annealing temperature, ion concentration (especially...

New inhibitors of human cytomegalovirus (HCMV) on the horizon.

1079 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...